Alkem Laboratories net profit rises 4.2% to ₹305.9 crore in Q4FY25

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Alkem Laboratories Ltd. on Thursday reported a 4.2% year-on-year (YoY) rise in  fourth-quarter net profit (after minority interest) to ₹305.9 crore.

The Mumbai-based pharmaceutical company’s total revenue from operations for the fourth quarter grew by 7.1% year-on-year to ₹3143.8 crore.

For the fourth quarter, however, the EBITDA margin contracted to 12.4% from 13.7% in the same period last year.

The company’s India sales were a significant contributor, rising 8.1% to ₹2135.5 crore. International sales also saw an increase, growing by 7.2% to ₹974.7 crore.

For the full fiscal year, net profit climbed 20.6% to ₹2165.5 crore. Alkem’s total revenue from operations increased by a modest 2.3% to ₹12,964.5 crore. This was primarily driven by a 6.5% growth in India sales, which reached ₹8983.7 crore. However, international sales for the year saw a de-growth of 4.5%.

The company's EBITDA margin for the full year expanded by 170 basis points to 19.4%. Annual EBITDA increased by 11.9% to ₹2512.2 crore.

In the Indian market, Alkem's growth was 6.8% for the full year, compared to the Indian Pharmaceutical Market's (IPM) growth of 7.7%, according to IQVIA data. The company's acute segment outperformed the IPM by 30 basis points in FY25.

Research and development expenses for FY25 were 4.3% of total revenue. The company filed 9 abbreviated new drug applications (ANDAs) with the USFDA and received 14 approvals during the year.

The company's cash and bank balance stood at ₹4620 crore as of March 31, 2025.